Berry Global, Inc.’s Post

According to our research the global market for medical devices is estimated at US$ 603 billion in the year 2023 and will be growing at a CAGR of 5% during next six years. #GlobalIncretinMimeticsMarket #DiabetesTreatment #Exenatide #Liraglutide #Lixisenatide #Albiglutide #SolidTumors #BloodRelatedTumors #MedicalDevicesMarket #MarketGrowth

According to our research the global market for medical devices is estimated at US$ 603 billion in the year 2023 and will be growing at a CAGR of 5% during next six years. #HematologyAnalyzers #MedicalDevices #HealthcareInnovation #BloodDiagnostics #HospitalEquipment #LaboratoryTools #GlobalMarket #MedicalTechnology #DiagnosticTools #HealthcareGrowth

According to our research the global market for medical devices is estimated at US$ 603 billion in the year 2023 and will be growing at a CAGR of 5% during next six years. #GlobalLeucogenMarket #HealthcareIndustry #MedicalDevices #Leucogen #HospitalPharmacies #RetailPharmacies #OnlinePharmacies #MedicalTechnology #HealthcareServices #MarketGrowth

Which of the following options is incorrect regarding the pharmacological management of BPH? Alpha-1 adrenergic blockers 5-alpha reductase inhibitors Nonsteroidal anti-inflammatory drugs (NSAIDs) Phosphodiesterase-5 inhibitors Explanation: Nonsteroidal anti-inflammatory drugs (NSAIDs) Nonsteroidal anti-inflammatory drugs (NSAIDs) are not commonly used in the pharmacological management of BPH. BPH is a condition characterised by the enlargement of the prostate gland, leading to urinary symptoms. The mainstay of pharmacological treatment for BPH includes alpha-1 adrenergic blockers and 5-alpha reductase inhibitors. 1) Alpha-1 adrenergic blockers: These medications relax the smooth muscles in the prostate and bladder neck, improving urine flow and reducing symptoms such as urinary frequency, urgency, and hesitancy. 2) 5-alpha reductase inhibitors: These drugs inhibit the conversion of testosterone to dihydrotestosterone (DHT), which is responsible for prostate growth. By reducing DHT levels, these medications can shrink the prostate gland and alleviate symptoms. 3) Phosphodiesterase-5 inhibitors: While primarily used for erectile dysfunction, phosphodiesterase-5 inhibitors like tadalafil (Cialis) have also shown some efficacy in relieving lower urinary tract symptoms associated with BPH. However, NSAIDs are not typically used in the management of BPH. NSAIDs are commonly used for pain relief and reducing inflammation, but they do not directly target the underlying causes or symptoms of BPH. Other treatment options, such as surgery or minimally invasive procedures, may be considered for BPH if medications fail to provide adequate relief.

The BD MiniDraw™ Capillary Blood Collection System is front and center in this Fast Company interview with Dave Hickey, EVP & president, BD Life Sciences. “We’re putting an innovative new blood-collection experience at consumers’ fingertips. Literally.” The innovative device is less invasive than a traditional venous blood draw because it collects blood from the tip of the finger, obtaining samples that produce lab-quality results. The ease of fingertip collection, coupled with the convenience of availability in non-traditional settings such as retail pharmacies, has the potential to transform blood collection for diagnostic testing. BD MiniDraw™ is yet another example of BD’s commitment to developing reliable, transformative solutions that deliver positive patient impact. https://lnkd.in/eDCMj-9j

The BD MiniDraw™ Capillary Blood Collection System is front and center in this Fast Company interview with Dave Hickey, EVP & president, BD Life Sciences. “We’re putting an innovative new blood-collection experience at consumers’ fingertips. Literally.” The innovative device is less invasive than a traditional venous blood draw because it collects blood from the tip of the finger, obtaining samples that produce lab-quality results. The ease of fingertip collection, coupled with the convenience of availability in non-traditional settings such as retail pharmacies, has the potential to transform blood collection for diagnostic testing. BD MiniDraw™ is yet another example of BD’s commitment to developing reliable, transformative solutions that deliver positive patient impact. https://lnkd.in/eDCMj-9j

According to our research the global market for medical devices is estimated at US$ 603 billion in the year 2023 and will be growing at a CAGR of 5% during next six years. #GlobalHematopathology #ClinicalLaboratoryServices #HealthcareInnovation #MedicalDevicesMarket #PatientCare #BloodDisorders #DiagnosticServices #HematologyResearch #MedicalResearch #HealthcareGrowth

Delighted to present our first review on microneedles. https://lnkd.in/dKSA25Sr. We discussed the current trends observed in the microneedle landscape, with particular emphasis on contemporary clinical trials and commercial successes. Additionally, we examined the barriers impeding microneedle development and commercialization. #Microneedles #ClinicalTrials #HealthcareInnovation #Research #MedicalTechnology